Loading
6 slides generated from the front page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Cutting off the hormones that some cancers, especially breast and prostate, need to grow.
Hormonal therapy groups the treatments that cut off the hormones some cancers, especially breast and prostate, need to grow. It spans aromatase inhibitors, SERMs, SERDs including fulvestrant, oral SERDs and PROTAC degraders such as vepdegestrant, ovarian suppression, androgen deprivation and AR pathway inhibitors, combined with CDK4/6, PI3K/AKT or PARP inhibitors depending on the tumour. Technologies linking here include endocrine therapy, CDK4/6 inhibitors, androgen deprivation and AR pathway inhibitors, and fertility-sparing hormonal treatment of early endometrial cancer. Companies such as Sumitomo Pharma, ESSA Pharma, Eli Lilly and Menarini, the person Bernard Fisher, and ideas on primary endocrine therapy for the frail elderly and low-dose tamoxifen also point here.